Chairman Charles E. Grassley, right, and ranking member Sen. Ron Wyden are seen before a Senate Finance Committee on drug pricing in America on February 26, 2019. (Tom Williams/CQ Roll Call)
Both the House and the Senate have competing bills aimed at addressing the rising costs of prescription drugs, a legislative priority backed by President Donald Trump.
But what would these various proposals accomplish, and how likely is it they’ll be signed into law?
[jwp-video n=”1″]
Recent Stories
Trump puts Italy’s Meloni in high-pressure role as bridge to EU on tariffs
Supreme Court to review Trump birthright citizenship order
At the Races: Only the young
California sues to stop tariffs levied under economic emergency
5 takeaways from first-quarter fundraising reports
Judge starts contempt of court process over US immigration moves
